BOSTON , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced the launch of p53reactivation.com .
BOSTON , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc. , (NASDAQ: APRE ), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced that the U.S.
BOSTON , Sept. 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc. , (NASDAQ: APRE ), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Michael A.
BOSTON , Sept. 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc. , (NASDAQ: APRE ), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the promotion of Gregory S.
BOSTON , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the Company is scheduled to present at
BOSTON , Aug. 11, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today reported financial results for the three and six months
Commenced expansion cohort in combination with venetoclax and azacitidine Added cohort to be activated in combination with azacitidine BOSTON , July 16, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel
BOSTON , June 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc. , (NASDAQ: APRE ), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointments of Fouad Namouni,
57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients 12.1 months median OS in intention-to-treat MDS patients with 9.7 months median duration of follow-up 13.7 months median OS in patients receiving 3 or more cycles of therapy with 9.7 months duration of follow-up BOSTON , June 12,
Topline data expected by year-end 2020 Applications for US and EU regulatory approval planned for 2021 BOSTON , June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that
